Repligen Corporation
RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pā¦ read more
Healthcare
Medical Instruments & Supplies
39 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$142.82
Price-1.49%
-$2.16
1Y
Price
Market Cap
$8.039b
Mid
Price/Earnings 3y Avg5y Avg
14,282x
Premium
Premium
Financials Overview
Key metrics over the past few years+24.2%
EBITDA Margin+8.2%
Net Profit Margin+11.5%
Free Cash Flow MarginRevenue
$673.956m
+6.2%
1y CAGR-4.8%
3y CAGR+1.3%
5y CAGREarnings
-$13.827m
+45.8%
1y CAGR-68.9%
3y CAGR-40.4%
5y CAGREPS
$0.08
+117.4%
1y CAGR-45.4%
3y CAGR-22.9%
5y CAGRBook Value
$2.062b
$2.902b
Assets$839.886m
Liabilities$686.064m
DebtDebt to Assets
23.6%
5.1x
Debt to EBITDAFree Cash Flow
$103.810m
-27.1%
1y CAGR+52.2%
3y CAGR+34.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company